Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NM1F |
| Synonyms | |
| Therapy Description |
NM1F is a monoclonal antibody that binds to PVRIG (CD112R) expressed on cytotoxic T-lymphocytes and NK cells and prevents its interaction with CD112, which potentially results in increased antitumor immune response and decreased tumor cell proliferation (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NM1F | NM 1F|NM-1F | PVRIG Antibody 5 | NM1F is a monoclonal antibody that binds to PVRIG (CD112R) expressed on cytotoxic T-lymphocytes and NK cells and prevents its interaction with CD112, which potentially results in increased antitumor immune response and decreased tumor cell proliferation (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |